Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 45-52

  Alibhai, Arif ^a   Kipp, Walter ^a   Duncan Saunders, L ^a   Senthilselvan, Ambikaipakan ^a   Kaler, Amy ^a   Houston, Stan ^a   Konde Lule, Joseph ^b   Okech Ojony, Joa ^c   Rubaale, Tom ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAKERERE UNIVERSITY   (Uganda)

^c Kabarole Health Department   (Uganda)

Author keywords

Antiretroviral treatment; Gender; Rural; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; EDUCATION; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RURAL AREA; SEX DIFFERENCE; SURVIVAL RATE; UGANDA;

EID: 77953388331     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/ijwh.s9408     Document Type: Article

References (41)

1. Mathers CD, Sadana R, Salomon JA, Murray CJL, Lopez AD. Healthy life expectancy in 191 countries, 1999. Lancet. 2001;357(9269): 1685-1691.
2. US Census Bureau. Global Population Profile: 2002. Washington, DC: US Government Printing Office; 2004.
3. UNAIDS. AIDS epidemic update: November 2009. Geneva, Switzerland: Joint United Nations Programme on AIDS; 2009.
4. Baghdadi G. Gender and medicines: An international public health perspective. J Womens Health. 2005;14(1):82-86.
5. Ojikutu BO, Stone VE. Women, inequality, and the burden of HIV. N Engl J Med. 2005;352(7):649-652.
6. Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: A systematic review. J Antimicrob Chemother. 2007;60(4):724-732.
7. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19(6):577-583.
8. Chen SCC, Yu JKL, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13(4):513-519.
9. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20(18):2355-2360.
10. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health. 2009;14(1):36-43.
11. Desilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care. 2009;21(1): 70-77.
12. Mujugira A, Wester CW, Kim S, Bussmann H, Gaolathe T. Patients with advanced HIV type 1 infection initiating antiretroviral therapy in Botswana: Treatment response and mortality. AIDS Res Hum Retroviruses. 2009;25(2):127-133.
13. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: Implications for program evaluation. Clin Infect Dis. 2006;43(6):770-776.
14. Braga PE, Cardoso MRA, Segurado AC. Gender differences among persons with HIV admitted to a university reference center in Sao Paulo, Brazil. Cadernos De Saude Publica. 2007;23(11):2653-2662.
15. Santoro-Lopes G, Harrison LH, Moulton LH, et al. Gender and survival after AIDS in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19(4):403-407.
16. Braitstein P, Brinkhof MWG, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-824.
17. Kaleebu P, Pillay D, Walker AS, et al. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20(10):1391-1399.
18. Wolbers M, Battegay M, Hirschel B, et al. CD4(+) T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther. 2007;12(6):889-897.
19. Porter K, Walker S, Hill T, et al. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 cells/mm(3). J Acquir Immune Defic Syndr. 2008;47(2): 202-205.
20. Smith CJ, Sabin CA, Youle MS, et al. Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients the role of gender. J Acquir Immune Defic Syndr. 2007;46(1):62-67.
21. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender - Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST study). J Acquir Immune Defic Syndr. 2008;47(4):441-448.
22. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JSG, Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol. 2002;31(5):1016-1020.
23. Boulassel MR, Morales R, Murphy T, Lalonde RG, Klein MB. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons. J Med Virol. 2006;78(9):1158-1163.
24. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active Antiretroviral therapy-treated women in Botswana - Preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007;46(3):318-322.
25. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: Findings from a multicenter collaboration. J Womens Health. 2008;17(1):47-55.
26. Kuyper LM, Wood E, Montaner JSG, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr. 2004;37(4):1470-1476.
27. Holstad MKM, Pace JC, De AK, Ura DR. Factors associated with adherence to antiretroviral therapy. J Assoc Nurses AIDS Care. 2006;17(2):4-15.
28. Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the southeastern United States. South Med J. 2007;100(8):775-781.
29. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDs. 2006;20(4):245-257.
30. Floris-Moore M, Lo YT, Klein RS, et al. Gender and hospitalization patterns among HIV-Infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34(3):331-337.
31. Kabarole District. District Information Portal. Available from: http://www.kabarole.go.ug/. Accessed August 12, 2008.
32. Uganda Ministry of Health. Uganda HIV/AIDS sero-behavioral survey 2004-2005. Kampala, Uganda: Uganda Ministry of Health; 2006.
33. Uganda Ministry of Health. National antiretroviral treatment and care guidelines for adults and for children. 1st Edition. Kampala, Uganda: Uganda Ministry of Health; 2003.
34. Kipp W, Konde-Lule J, Saunders LD, et al. Results of a community-based antiretroviral treatment program for HIV-1 infection in western Uganda. Curr HIV Res. 2010 Feb 18. [Epub ahead of print].
35. Hosmer D, Lemeshow S, May S. Applied Survival Analaysis. Regression Modeling of Time-to-Event Data (2nd Edition). Hoboken, NJ: John Wiley & Sons Inc.; 2008.
36. Collett D. Modelling Survival Data in Medical Research. London, UK: Chapman and Hall; 1994.
37. STATA Statistical Software: Release 10.0 [computer program]. College Station, TX: Stata Corporation; 2001.
38. Dunne MT, Ruskin HJ, Mulcahy FM. Survival with AIDS in Ireland. AIDS. 1997;11(10):1281-1290.
39. Okong P. HIV/AIDS and women's health in Uganda: Lingering gender inequity. J Obstetr Gynaecol Canada. 2006;28:980-982.
40. Lawn S, Little F, Bekker L, et al. Changing mortality risk associated with CD4 cell response to long-term ART: sub-Saharan Africa. Montreal, Canada: Paper presented at Sixteenth Conference on Retroviruses and Opportunistic Infections; 2009.
41. Brinkhof M, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting ART: Comparisons with the general population in Southern Africa. Montreal, Canada: Paper presented at: Sixteenth Conference on Retroviruses and Opportunistic Infections; 2009.